Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EPS (Weighted Average and Diluted) (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.34 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 585.71% year-over-year to -$0.34, compared with a TTM value of -$0.52 through Dec 2025, down 940.0%, and an annual FY2025 reading of -$0.52, down 940.0% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.34 for Q4 2025 at Cytek Biosciences, down from -$0.05 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.07 in Q2 2021 and bottomed at -$0.34 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.04, with a median of -$0.04 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 600.0% in 2023, then surged 120.0% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.07 in 2021, then tumbled by 59.65% to $0.03 in 2022, then soared by 33.33% to $0.04 in 2023, then surged by 75.0% to $0.07 in 2024, then crashed by 585.71% to -$0.34 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CTKB at -$0.34 in Q4 2025, -$0.05 in Q3 2025, and -$0.04 in Q2 2025.